CollPlant Biotechnologies announced on September 30, 2025, positive results from its non-clinical program evaluating its photocurable dermal filler. This novel filler integrates contouring precision, structural support, and tissue regeneration into a single treatment, representing a significant breakthrough in aesthetic medicine.
The non-clinical program included a comprehensive set of safety and performance evaluations, notably a one-year in vivo study confirming long-term durability and biocompatibility assessments that complied with international standards. These combined results establish a strong foundation for clinical advancement.
CollPlant is now preparing to advance this product candidate into clinical trials and is scaling and optimizing its manufacturing process to ensure readiness. The filler combines hyaluronic acid with a modified form of rhCollagen, administered as a viscoelastic gel that is then stabilized by light activation into a semi-solid, cohesive implant.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.